Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis
Launched by HACETTEPE UNIVERSITY · Oct 29, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how people with Idiopathic Pulmonary Fibrosis (IPF) compare to healthy individuals in terms of their exercise capacity, breathing abilities, and muscle strength. The goal is to better understand how IPF affects these functions, as there isn't enough research on this topic yet.
To participate, you need to be at least 18 years old and have a confirmed diagnosis of IPF. It's important that you're in a stable phase of the disease and haven't had any respiratory infections in the last month. However, if you've experienced a serious IPF attack recently or have other significant health issues, you won't be eligible. If you join the study, you can expect to take part in various assessments that will help researchers learn more about IPF and how it impacts daily life. This information could be really valuable in improving care for patients with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being over 18 years old
- • having a clinical, radiological and/or pathological diagnosis of IPF
- • volunteering to participate in the study
- • not having had a respiratory tract infection in the last month
- • not having an accompanying airway disease such as COPD
- • being in the stable phase of the disease
- Exclusion Criteria:
- • Patients who have had an IPF attack within the last three months and/or are in the acute exacerbation of the disease; who use a walking aid; who have unstable angina or class III-IV heart failure according to the New York Heart Association congestive heart failure classification; who have orthopedic, neuromuscular, neurological and cardiac diseases that may affect walking and balance; who have serious comorbid conditions such as cancer or neoplasm; who have a history of sarcoidosis, tuberculosis, emphysema and/or lung surgery; who have communication problems, mental and cognitive problems, and who cannot adapt to the applied assessment methods will be excluded from the study.
About Hacettepe University
Hacettepe University is a leading research institution in Turkey, renowned for its commitment to advancing medical science and healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, the university supports a wide range of clinical trials aimed at improving patient outcomes and developing new therapeutic approaches. Hacettepe University is dedicated to maintaining the highest ethical standards and regulatory compliance in its research endeavors, fostering an environment that promotes scientific excellence and contributes to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported